Gilead Sciences, Inc. $GILD Shares Purchased by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 334.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 48,825 shares of the biopharmaceutical company’s stock after acquiring an additional 37,591 shares during the quarter. Global X Japan Co. Ltd.’s holdings in Gilead Sciences were worth $5,993,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC raised its holdings in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Laurel Wealth Advisors LLC lifted its position in Gilead Sciences by 10,988.3% in the second quarter. Laurel Wealth Advisors LLC now owns 6,653 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 6,593 shares during the period. Finally, J.W. Cole Advisors Inc. boosted its holdings in Gilead Sciences by 6.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 23,081 shares of the biopharmaceutical company’s stock valued at $2,559,000 after purchasing an additional 1,354 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.0%

Shares of GILD stock opened at $136.88 on Friday. The company has a market capitalization of $169.90 billion, a price-to-earnings ratio of 20.22, a PEG ratio of 1.81 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a 50-day moving average price of $143.90 and a 200 day moving average price of $128.44. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the business posted $1.90 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is 48.45%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. HSBC raised their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. BMO Capital Markets upped their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, January 26th. Wolfe Research upped their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Monday, February 23rd. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.62.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the sale, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 309,280 shares of company stock worth $44,068,850 in the last three months. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.